12926
中文   |   English 手机浏览
Yanxin Luo M.D. Ph.D The Sixth Affiliated Hospital of Sun Yat-sen University
Yanxin Luo M.D. Ph.D The Sixth Affiliated Hospital of Sun Yat-sen University Chief Physician, Doctoral Supervisor, Postdoctoral Supervisor Assistant to the Dean Director of Molecular Diagnostic Center, Department of Clinical Laboratory Medicine Director of the Human Resources Department (concurrently) Dr. Yanxin Luo obtained his Bachelor's degree (2006) and Doctoral degree (2011) from Sun Yat-sen University School of Medicine, and completed his postdoctoral training in the United States from September 2009 to September 2013. With an international perspective, he has received systematic training both domestically and abroad, specializing in the molecular mechanisms of gastrointestinal tumor development and clinical translation. His clinical expertise lies in the detection, diagnosis and treatment of colorectal cancer, with a focus on scientific questions such as predicting colorectal cancer occurrence and mitigating recurrence and metastasis post-treatment. Dr. Luo has successively led five projects of the National Natural Science Foundation of China, the "Outstanding Youth" project of the Natural Science Foundation of Guangdong Province, and participated in the National Key Programs of China. He has authored over 80 SCI papers and holds nine authorized patents, and was the first to systematically elucidate a novel DNA methylation regulation mechanism in the malignant transformation of colorectal adenomas (Gastroenterology, 2014, Sole First and Co-corresponding Author). In the past 5 years, Dr. Luo has conducted in-depth research building upon the aforementioned foundation and made significant academic contributions, including (1) pioneering revelation that DNA methylation can control adenoma carcinogenesis and promote post-cancer cell progression through targeted regulation of actin and microtubules (Cancer Research, 2020, Sole Corresponding Author); (2) These key loci control the biological behaviors of tumors (Clinical Chemistry, 2019, Sole Corresponding Author), which provide important intervention targets for CRC treatment and prognosis (Journal of the National Cancer Institute, 2023, Last Corresponding Author); (3) Demonstrating that DNA methylation of non-tumor cells in the microenvironment can serve as cellular molecular tags for evaluating CRC immune response (Journal for Immunotherapy of Cancer, 2021, Last Corresponding Author), influence the biological behavior of the tumor (eBioMedicine, 2023, Last Corresponding Author), and also impact immunotherapy outcome (Journal for Immunotherapy of Cancer, 2022, Last Corresponding Author).
Huichuan Yu M.D. Ph.D The Sixth Affiliated Hospital of Sun Yat-sen University
Huichuan Yu, MD., Ph.D., Associate Professor in The Sixth Affiliated Hospital, Sun Yat-sen University. He is an Active Member of American Association for Cancer Research (AACR). His current research interests include developing novel biochemical assays and in silico tools to map genetic and epigenetic features in human cells with different states, exploring the epigenetic mechanisms and processes involved in the development of gastrointestinal carcinomas, and identifying novel biomarkers to provide the most effective care for cancers. He has published over 30 research articles in multiple peer-reviewed journals such as JAMA Oncol, Nature Commun, J Natl Compr Canc Netw, J Immunother Cancer, and Clinical Chemistry.
Xiaoxia Liu Ph.D The Sixth Affiliated Hospital of Sun Yat-sen University
Her current research interests are in basic and clinical translational research of tumors, the mechanism of tumor malignancy progression regulated by metabolic reprogramming in tumor microenvironment and the exploration of new treatment strategies. She has published over 10 research articles in multiple peer-reviewed journals such as Nucleic Acids Res, eBiomedicine, Redox Biology, Journal for ImmunoTherapy of Cancer, Int. J. Biol. Sci, MOL ONCOL.
Xiaolin Wang Ph.D The Sixth Affiliated Hospital of Sun Yat-sen University
Dr. Xiaolin Wang is a Senior Staff Scientist with a comprehensive research background in the field of Molecular Biology. She has dedicated her career to investigating the roles and mechanisms of G-quadruplexes in inflammatory diseases and cancer, as well as advancing clinical chemical detection of cancer biomarkers. Her pioneering research has led to significant discoveries in the field. Her notable contributions include the discovery that diazobenzene compounds can induce reversible light-mediated control of G-quadruplex structures (Angew Chem Int Ed Engl, 2010, Hot Paper; Org Biomol Chem, 2011). In recent years, she has been at the forefront of research on the involvement of G-quadruplexes in the onset and progression of inflammatory diseases and cancer, exploring the intricate interplay between inflammation and cancer. Dr. Xiaolin Wang has led and collaborated on numerous national and provincial-level research projects, resulting in the publication of over 30 influential SCI papers in esteemed journals such as Clin Transl Med(2023), BMC Cancer(2023), iScience(2022), J ImmunoTher Cancer(2021), etc.
Jinxin Lin M.D. PhD The Sixth Affiliated Hospital of Sun Yat-sen University
His primary research focus is on the standardized treatment of colorectal cancer. He specializes in laparoscopy-assisted colorectal tumor surgery, anal-preserving surgery for lower rectal cancer, and Natural Orifice Specimen Extraction Surgery (NOSES).
Binbin Liu M.D. PhD The Sixth Affiliated Hospital of Sun Yat-sen University
Research More >
We focuses on the development of colorectal cancer, conducting research in the fields of tumor epigenetics, clinical proteomics, and translational medicine. We have undertaken 10 projects funded by the National Natural Science Foundation, 6 projects funded by provincial and ministerial-level research funds, and the Guangdong Provincial Outstanding Youth Program Grant. We have also participated in National Basic Research Program, and National Key Research and Development Program of China.
Events More >
Useful Links
You are the 12926 visitor